Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis

M. Furue; K. Yamamura; M. Kido‐Nakahara; T. Nakahara; Y. Fukui

doi:10.1111/all.13239

journal article Open Access Jul 20, 2017

Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis

M. Furue K. Yamamura M. Kido‐Nakahara T. Nakahara

Y. Fukui

Allergy Vol. 73 No. 1 pp. 29-36 · Wiley

View at Publisher Save 10.1111/all.13239

Abstract

AbstractAtopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)‐deviated immune reactions. Interleukin‐31 (IL‐31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti‐IL‐31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL‐31 and its receptor with special references to atopic itch.

Topics

No keywords indexed for this article. Browse by subject →

References

77

[1]

10.1016/s0140-6736(15)00149-x

[2]

10.1111/1346-8138.13392

[3]

10.1016/j.jdermsci.2009.09.008

[4]

10.1111/1346-8138.13060

[5]

10.1001/archpedi.159.8.745

[6]

10.2340/00015555-1360

[7]

10.1016/j.jdermsci.2015.05.010

[8]

10.1016/j.jaci.2013.10.048

[9]

10.1016/j.iac.2016.08.007

[10]

10.1111/1346-8138.12726

[11]

10.1038/nn.3289

[12]

10.1007/978-3-662-44605-8_3

[13]

10.1038/ni1084

[14]

10.1111/bph.12823

[15]

10.1111/j.1365-3164.2012.01098.x

[16]

10.1111/jvp.12101

[17]

10.1111/vde.12280

[18]

10.1111/jdv.13794

[19]

Oyama S "Cynomolgus monkey model of interleukin‐31‐induced scratching depicts blockade of human interleukin‐31 receptor A by a humanized monoclonal antibody" Exp Dermatol (2016)

[20]

10.1111/all.12316

[21]

10.1111/bjd.14207

[22]

10.1056/nejmoa1606490

[23]

10.1016/j.cytogfr.2008.08.003

[24]

10.1016/j.jaci.2005.10.046

[25]

10.1016/j.vetimm.2013.10.017

[26]

Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis

Atsuhiko Kato, Etsuko Fujii, Takeshi Watanabe et al.

Journal of Dermatological Science 10.1016/j.jdermsci.2014.02.009

[27]

10.1111/cea.12875

[28]

10.4049/jimmunol.0900712

[29]

10.1038/jid.2015.106

[30]

10.1371/journal.pone.0067666

[31]

10.4049/jimmunol.1301836

[32]

10.1016/j.jaci.2013.03.050

[33]

10.1074/jbc.m115.661306

[34]

10.1016/j.jaci.2005.10.033

[35]

Staphylococcal α-Toxin Induces a Higher T Cell Proliferation and Interleukin-31 in Atopic Dermatitis

Margarete Niebuhr, Diana Mamerow, Annice Heratizadeh et al.

International Archives of Allergy and Immunology 10.1159/000323905

[36]

Diveu C "Predominant expression of the long isoform of GP130‐like (GPL) receptor is required for interleukin‐31 signaling" Eur Cytokine Netw (2004)

[37]

10.1074/jbc.m401122200

[38]

10.1111/j.1398-9995.2011.02545.x

[39]

10.1111/all.12152

[40]

10.4049/jimmunol.1101044

[41]

10.1074/jbc.m114.622126

[42]

10.1084/jem.20061791

[43]

10.1182/blood-2003-02-0367

[44]

10.1186/s13223-017-0194-9

[45]

10.4049/jimmunol.0902769

[46]

10.1016/j.cytogfr.2015.07.006

[47]

10.1111/all.13065

[48]

10.1016/j.alit.2016.12.002

[49]

10.1056/nejmoa1610020

[50]

10.1111/1346-8138.13231

Showing 50 of 77 references

Cited By

198

Molecular Mechanisms of Neurogenic Inflammation of the Skin

Luiza Marek-Jozefowicz, Bogusław Nedoszytko · 2023

International Journal of Molecular...

Cytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis

Mélanie Humeau, Katia Boniface · 2022

Frontiers in Immunology

The IL-4, IL-13 and IL-31 pathways in atopic dermatitis

Celina Dubin, Ester Del Duca · 2021

Expert Review of Clinical Immunolog...

Interleukin‐31: The “itchy” cytokine in inflammation and therapy

Angeliki Datsi, Martin Steinhoff · 2021

Allergy

Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment

Laura Rojas Lorz, Mi-Yeon Kim · 2020

Journal of Ginseng Research

A randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis

Kyunguk Jeong, Se Ah Jeon · 2020

Pediatric Allergy and Immunology

Type 2 immunity in the skin and lungs

Cezmi A. Akdis, Peter D. Arkwright · 2020

Allergy

Metrics

198

Citations

77

References

Details

Published: Jul 20, 2017
Vol/Issue: 73(1)
Pages: 29-36
License: View

Authors

M

M. Furue

Department of Dermatology and Division of Skin Surface Sensing Graduate School of Medical Sciences Kyushu University Fukuoka Japan; Research and clinical center for Yusho and dioxin Kyushu University Hospital Kyushu University Fukuoka Japan

K

K. Yamamura

Department of Dermatology and Division of Skin Surface Sensing Graduate School of Medical Sciences Kyushu University Fukuoka Japan

M

M. Kido‐Nakahara

Department of Dermatology and Division of Skin Surface Sensing Graduate School of Medical Sciences Kyushu University Fukuoka Japan

T

T. Nakahara

Department of Dermatology and Division of Skin Surface Sensing Graduate School of Medical Sciences Kyushu University Fukuoka Japan

Y

Y. Fukui

Division of Immunogenetics Department of Immunobiology and Neuroscience Medical Institute of Bioregulation Kyushu University Fukuoka Japan; Research Center for Advanced Immunology Kyushu University Fukuoka Japan

Funding

Ministry of Education, Culture, Sports, Science and Technology

Cite This Article

M. Furue, K. Yamamura, M. Kido‐Nakahara, et al. (2017). Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis. Allergy, 73(1), 29-36. https://doi.org/10.1111/all.13239

Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis

You May Also Like